WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007014459) CANCEROUS DISEASE MODIFYING ANTIBODIES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/014459    International Application No.:    PCT/CA2006/001250
Publication Date: 08.02.2007 International Filing Date: 01.08.2006
IPC:
C12P 21/08 (2006.01), A61P 35/00 (2006.01), A61K 39/395 (2006.01), C07K 16/18 (2006.01), C07K 16/30 (2006.01), C07K 16/46 (2006.01), C12N 5/16 (2006.01), G01N 33/567 (2006.01), G01N 33/574 (2006.01)
Applicants: ARIUS RESEARCH, INC. [CA/CA]; 55 York Street, 16th Floor, Toronto, Ontario M5J 1R7 (CA)
Inventors: YOUNG, David, S., F.; (CA).
HAHN, Susan, E.; (CA).
CECHETTO, Lisa, M.; (CA)
Agent: SINGLEHURST, John, C.; Finlayson & Singlehurst, 70 Gloucester Street, Ottawa, Ontario K2P 0A2 (CA)
Priority Data:
60/705,073 02.08.2005 US
Title (EN) CANCEROUS DISEASE MODIFYING ANTIBODIES
(FR) ANTICORPS CAPABLES DE MODIFIER L'EVOLUTION D'UNE MALADIE CANCEREUSE
Abstract: front page image
(EN)The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
(FR)L'invention se rapporte à une méthode permettant de produire des anticorps capables de modifier l'évolution d'une maladie cancéreuse chez un patient à l'aide d'un nouveau paradigme de criblage. Le procédé, qui consiste à isoler des anticorps anticancéreux en utilisant la cytotoxicité des cellules cancéreuses pour résultat final, permet de produire des anticorps anticancéreux destinés à un usage thérapeutique et diagnostique. On peut utiliser ces anticorps pour stadifier et diagnostiquer un cancer, et pour traiter des tumeurs primaires et des métastases tumorales. Ces anticorps anticancéreux peuvent être conjugués à des toxines, des enzymes, des composés radioactifs et des cellules hématogènes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)